Trial Profile
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary) ; Salmeterol/fluticasone propionate
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors ALTANA Pharma
- 29 May 2012 New trial record